此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

急性脊髓损伤经皮胫神经刺激 (TASCI)

2026年11月2日 更新者:University of Zurich

急性脊髓损伤患者经皮胫神经刺激预防神经源性逼尿肌过度活动:一项全国随机、假对照、双盲临床试验

Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. Neuromodulation procedures are a promising avenue so that we investigate the effect of transcutaneous tibial nerve stimulation (TTNS) in patients with acute SCI.

This nationwide randomized, sham-controlled, double-blind multicentre clinical trial includes all SCI centres in Switzerland (Basel, Nottwil, Sion, Zürich). Patients are randomly assigned to VERUM TTNS (active stimulation, n=57) and SHAM stimulation (n=57) groups in a 1:1 allocation using computer-generated permuted block randomisation lists stratified on study centre and lower extremity motor score. Daily 30-minute sessions are performed five times a week during an intervention period of 6-9 weeks. The primary outcome of this study is the success of TTNS to prevent neurogenic DO jeopardizing the upper urinary tract, assessed by urodynamics at 1 year after SCI or any earlier time point if DO treatment is necessary (study end). Secondary outcome measures are bladder diary parameters, clinical symptom scores assessed by standardized and validated questionnaires. Furthermore, neurophysiological and neuroimaging outcome measures are assessed as well as, biochemical and molecular changes. Tertiary outcome measure is the safety of TTNS.

Before the actual start of the TASCI RCT, start-up activities will include a piloting phase on groups of healthy volunteers and patients. The goal during this phase is to evaluate the feasibility of the experimental setup, in particular for the TTNS and SHAM intervention, but also to test the setup of the different pre and post assessments (e.g. neurophysiology and neuroimaging tests). Groups of up to 15 participants each will be enrolled in a few consecutive pilot studies allowing for fine tuning and small adaptations in between, if appropriate.

研究概览

研究类型

介入性

注册 (估计的)

114

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Basel、瑞士
        • 招聘中
        • REHAB Basel
        • 接触:
        • 首席研究员:
          • Sandra Möhr, pract. med.
      • Nottwil、瑞士
        • 招聘中
        • Swiss Paraplegic Centre
        • 接触:
        • 首席研究员:
          • Jürgen Pannek, Prof. Dr. med.
      • Sion、瑞士
        • 招聘中
        • Spinal Cord Injury Department, Clinique romande de réadaption
        • 接触:
        • 首席研究员:
          • Xavier Jordan, Dr. med.
    • Canton of Zurich
      • Zurich、Canton of Zurich、瑞士、8008
        • 招聘中
        • Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University Hospital
        • 接触:
        • 首席研究员:
          • Thomas M Kessler, Prof. Dr. med.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age >18 years

  • Patients with acute SCI (traumatic SCI and sudden onset (<7 days) non-traumatic SCI) within 40 days after injury

  • Patients with acute SCI at cervical or thoracic level

  • Willing to take part and follow the requirements of the TASCI protocol (up to one year after SCI)

    • no percutaneous tibial nerve stimulation (PTNS)
    • no functional electrical stimulation (FES), apart from upper limb FES
    • no electrical muscle stimulation (EMS)
  • Informed Consent

Exclusion Criteria:

  • Contraindications to the investigational product
  • DO with contractions greater than 40 cmH2O at a bladder filling volume of less than 500mL at baseline visit
  • Treatment with antimuscarinics or with mirabegron
  • Known or suspected non-adherence, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another study with investigational drug or product within the 30 days preceding and during the present study
  • Neuromodulation treatment for urological or bowel indication in the last six months or ongoing
  • Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six months
  • Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude < 1mV)
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html])
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Pre-existing or concomitant medical condition apart from SCI that might pose a safety issue or would interfere with interpretation of study results or study conduct (e.g. Parkinson's disease, neurodegenerative disorders including multiple sclerosis and amyotrophic lateral sclerosis, urological malignancies)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:VERUM 经皮胫神经刺激 (TTNS)
  • Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments
  • During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase
假比较器:SHAM 经皮胫神经刺激 (TTNS)
  • Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments
  • During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The occurrence of neurogenic DO jeopardizing the upper urinary tract
大体时间:up to 12 months after SCI

Defined as composite measure: Urodynamic assessment establishing DO amplitude ≥40 cmH2O; or else initiation of DO treatment (with antimuscarinics and/or intradetrusor onabotulinumtoxinA injections)

up to 12 months after SCI

次要结果测量

结果测量
措施说明
大体时间
尿动力学期间膀胱顺应性 [mL/cmH2O] 的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
通过尿动力学评估的最大流速 [mL/s] 的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
尿动力学期间通过录像评估的膀胱输尿管肾返流 (VUR) 的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
尿动力学期间通过肌电图 (EMG) 评估的盆底活动的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
国际脊髓协会 (ISCoS) 女性/男性性功能数据集的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
肛门直肠测压和恒压器评估期间直肠顺应性 [mL/cmH2O] 的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
诱发电位 (EP) 的神经生理学测量值以及神经传导测量值的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
下尿路 (LUT) 神经生理学的变化:当前感知阈值 (CPT) 和 LUT 感觉诱发电位 (LUTSEP) 及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
膀胱组织、血液和尿液中炎症标志物的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
膀胱组织的变化及其与临床结果的关系
大体时间:基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
基线; SCI后3个月; SCI后6个月; SCI/研究结束后 12 个月
Volumetric changes during urodynamics and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Cystometric capacity [mL], volume at first DO [mL], voided volume [mL] and post void residual [mL] as assessed by urodynamic measurement

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Pressure changes during urodynamics and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Maximum DO amplitude [cmH2O], detrusor leak-point pressure [cmH2O], maximum detrusor pressure [cmH2O] during storage phase, maximum detrusor pressure [cmH2O] during voiding phase, detrusor pressure at maximum flow rate [cmH2O] as assessed by urodynamic measurement

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in bladder storage and voiding parameters and their relation to clinical outcomes
大体时间:Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Assessed by a bladder diary

Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in bowel diary parameters and their relation to clinical outcomes
大体时间:Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Assessed by a bowel diary

Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in International Prostate Symptom (IPSS) questionnaire and their relation to clinical outcomes
大体时间:Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The IPSS ("International Prostate Symptom Questionnaire") score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible."

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in urinary symptoms as assessed by the Urinary Symptom Profile (USP) questionnaire and their relation to clinical outcomes
大体时间:Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The USP ("Urinary Symptom Profile") score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic).

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Qualiveen questionnaire scores and their relation to clinical outcomes
大体时间:Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL).

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Female Sexual Function Index (FSFI) and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The FSFI ("Female Sexual Function Index") is based on questions concerning female sexual functions. It consists of 19 items covering 6 domains, namely sexual desire, arousal (both subjective and physiologic), lubrication, orgasm, satisfaction, and pain. The lowest possible score in the total FSFI is 2 (asymptomatic); the highest possible score is 36 (symptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in International Index of Erectile Function (IIEF) and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The IIEF ("International Index of Erectile Function") is based on questions concerning erectile dysfunction. It consists of 15 items covering 5 domains, namely erectile functioning, orgasmic functioning, sexual desire, and intercourse satisfaction along with a fifth component which encompasses the concept of overall sexual satisfaction. While items 1-10 are rated on a 6-point Likert-type scale from 0 to 5, items 11-15 are rated on a 5-point Likert-type scale from 1 to 5. Higher scores are reflecting less dysfunction. Domain scores are computed by summing the sores for individual items in each domain.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Neurogenic Bowel Dysfunction (NBD) score and their relation to clinical outcomes
大体时间:Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The NBD ("Neurogenic Bowel Dysfunction") score is based on questions concerning constipation and fecal incontinence and was developed for and validated in the spinal cord injury population. It consists of 10 items. The lowest possible score in the total NBD is 0 (asymptomatic); the highest possible score is 47 (symptomatic). The interpretation of the total NBD score is very minor NBD (0-6), minor NBD (7-9), moderate NBD (10-13), and severe NBD (≥14).The NBD score is assessed by using the international spinal cord injury (ISCoS) bowel function basic data set.

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Volumetric changes during rectal sensitivity testing and barostat assessment and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Initial sensation [mL], volume at urge to defecate [mL], maximum tolerated volume [mL] as assessed by rectal sensitivity testing; rectal capacity [mL] assessed by barostat assessment

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Pressure changes during anorectal manometry and barostat assessment and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Basal internal anal sphincter pressure [mmHg], squeeze external anal sphincter pressure [mmHg], relaxation internal anal sphincter pressure during defecation [%, mmHg], intraabdominal pressure during defecation [mmHg]

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in defecatory disorder [Rao's classification] identified during anorectal manometry and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Anorectal manometry is the preferable test for defecatory disorder. Rao's classification describes the four types of manometric patterns (I-IV) that are identified through manometric assessments

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) assessment to quantify the severity of the spinal cord injury

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Lower Extremities Motor Scale (LEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Upper Extremities Motor Scale (UEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Spinal Cord Independence Measure III (SCIM-III) and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in spasticity in the knee and elbow flexors and extensors from the Modified Ashworth Scale (MAS) assessment and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The MAS is a 5-point nominal scale that uses subjective clinical assessments of muscle tone ranging from 0 - 'No increases in tone' to 4 - 'Limb rigid in flexion or extension'. A grade of (1+) indicates resistance in the movement.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in spasticity in daily life as assessed by the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) questionnaire and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The SCI-SET ("Spinal Cord Injury Spasticity Evaluation Tool ") score is based on questions concerning the positive and negative effects of spasticity on different areas of daily life. Each of the 35 items are rated on a 7-point scale (-3=extremely problematic; 0=no effect; 3=extremely helpful). Calculations include counts and sum scores of areas of daily life where spasticity is problematic (count range: 0 to 35, sum score range: 35 to 0) or helpful (counts range: 0 to 35, sum score range: 0 to +35) as well as a mean score of all applicable items (range: -3 to +3)

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in frequency power of surface electromyography (EMG) and electroencephalography (EEG) and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Fast Fourier Transformation analysis for delta, theta, alpha, beta, and gamma band power as assessed via EEG of the cortex and EMG of the muscle

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in EMG and EEG coherence measures and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Coherence for EEG and EMG signals computed as cortico-muscular, inter- and intra-muscular coherence for typical EEG/EMG frequency bands (delta, theta, alpha, beta, and gamma).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter area in the lumbosacral enlargement (LSE) and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

White and gray matter areas are obtained by segmenting the T2*-weighted MRI images for white and gray matter at the level of LSE

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter area in upper cervical cord (at C2/C3) and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Obtained by segmenting the T2*-weighted MRI images for white and gray matter at the vertebral level C2/C3.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter volume of the conus medullaris (CM) and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

White and gray matter volume are obtained by segmenting the T2*-weighted MRI images for white and gray matter in the CM

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in gray and white matter volume in the brain and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Gray and white matter volume in the brain are computed by feeding the whole-brain T1-weighted MRI images into a voxel-based morphometry algorithm. Changes in the gray and white matter volume will be evaluated in urologically relevant brain areas.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in fractional anisotropy (FA) in the brain and spinal cord and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

FA is a common dimensionless measure used in Diffusion Tensor Imaging (DTI) studies and ranges from 0, isotropic movement of water molecules (e.g., cerebrospinal fluid), to 1, fully anisotropic movement of water molecules (e.g., fiber bundles).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in diffusivity in the brain and spinal cord and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Mean, axial, and radial diffusivity (MD, AD, RD) are common measures used in DTI studies providing information about the integrity of the underlying tissue.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in brain and spinal cord tissue microstructure and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Quantitative tissue parameters assessed using MRI Multi-Parameter Mapping.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Expression profile of microRNA (miRNA) in urine and blood as well as their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

MicroRNA (miRNA) sequencing is used to identify regulated miRNAs specific to TTNS intervention in urine and blood.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in levels of neurotransmitters (neurotrophins) in blood, and urine, as well as their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Analysis will be performed using ELISA to detect molecules likely to be involved in the underlying molecular mechanisms of neuromodulation.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in the composition of urinary and stool microbiome and their relation to clinical outcomes
大体时间:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Gut and bladder microbial patterns are determined from stool and urine samples

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

其他结果措施

结果测量
措施说明
大体时间
Incidence of side effects as well as number and intensity/severity (mild/moderate/severe) of adverse events (AEs) and serious adverse events (SAEs) for the following categories:
大体时间:During complete study period, up to 12 months
  • infection - Urinary Tract Infection (UTI)
  • infection - other than UTI
  • skin irritation at the electrode site
  • irritation-related symptoms (e.g. dysuria, hematuria) immediately following a LUT intervention
  • neuro-urological deterioration
  • pressure ulcer
  • neurological deterioration
  • increase in pain
  • increase in spasticity
  • deep vein thrombosis / pulmonary embolism
  • autonomic dysreflexia
  • transfer/admittance to an acute care facility
During complete study period, up to 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Thomas M. Kessler, Prof. Dr. med.、University of Zurich
  • 首席研究员:Thomas M. Kessler, Prof. Dr. med.、Balgrist University Hospital
  • 首席研究员:Armin Curt, Prof. Dr. med.、Balgrist University Hospital
  • 首席研究员:Jürgen Pannek, Prof. Dr. med.、Swiss Paraplegic Centre
  • 首席研究员:Martin Brinkhof, Dr.、Swiss Paraplegic Research, Nottwil

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年6月19日

初级完成 (估计的)

2028年9月30日

研究完成 (估计的)

2028年9月30日

研究注册日期

首次提交

2019年3月26日

首先提交符合 QC 标准的

2019年5月23日

首次发布 (实际的)

2019年5月29日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All individual participant data (IPD) and data dictionaries that underlie results in a publication are to be uploaded to a public data registry in cases where this can be done without compromising patient privacy. Given the small size of the dataset and that spinal cord injury (SCI) is a rare condition, to ensure identity protection any publicly available dataset(s) will be modified to reduce the number of indirect identifier variables, e.g. continuous variables such as age will be grouped, categorical or binary variables with small group numbers such as study centre will not be provided. When data sets cannot be sufficiently de-identified to be made publicly available, they will be made available upon reasonable request. Data judged to be confidential to participants or the participating study centers will not be released, but efforts will be made to provide scientifically meaningful equivalent information.

IPD 共享时间框架

Post-publication data packages, containing the analysis data set presented in scientific reports will be available starting 6 months after the publication date. Data that are not being prepared for publication will be available to secondary users starting 4 years after study completion or discontinuation. All data will be kept for at least 10 years after study completion or discontinuation.

IPD 共享访问标准

Requests for data access will be reviewed by the TASCI steering committee, which includes the four project PIs and representatives from each of the participating study centers. The steering committee will request a project plan, including at a minimum an abstract and a list of author names and roles, from the leaders of all projects wishing to use TASCI study data. Project plans will be evaluated on the basis of scientific validity, and also on whether they include adequate measures to protect patient privacy. Secondary users will be asked to sign a data use agreement.

IPD 共享支持信息类型

  • 分析代码

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅